Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis

References

• Federico M, Rudiger T, Bellei M, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2013;31(2):240–246.
   PubMed Web of Science ®Google Scholar
• de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol. 2010;148(5):673–689.
   PubMed Web of Science ®Google Scholar
• Lunning MA, Vose JM. T-cell lymphoma: the many-faced lymphoma. Blood. 2017;129(9):1095–1102.
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-Cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
   PubMed Web of Science ®Google Scholar
• Chihara D, Fanale MA, Miranda RN, et al. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017;176(5):750–758.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095–3100.
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182–1189.
   PubMed Web of Science ®Google Scholar
• Toumishey E, Prasad A, Dueck G, et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer. 2015;121(5):716–723.
   PubMed Web of Science ®Google Scholar
• Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103(8):2920–2924.
   PubMed Web of Science ®Google Scholar
• Park B-B, Kim WS, Suh C, et al. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. Ann Hematol. 2015;94(11):1845–1851.
   PubMed Web of Science ®Google Scholar
• Mikesch J-H, Kuhlmann M, Demant A, et al. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. Ann Hematol. 2013;92(8):1041–1048.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Prange E, Haferlach T, et al. High-dose chemotherapy and autologous bone marrow transplantation in relapsing angioimmunoblastic lymphadenopathy with dysproteinemia (AILD). Bone Marrow Transplant. 1991;8(6):503–506.
   PubMed Web of Science ®Google Scholar
• Lindahl J, Kimby E, Björkstrand B, et al. High-dose chemotherapy and APSCT as a potential cure for relapsing hemolysing AILD. Leuk Res. 2001;25(3):267–270.
   PubMed Web of Science ®Google Scholar
• Hong X, Song Y, Huang H, et al. Pralatrexate in Chinese patients with relapsed or refractory peripheral T-cell lymphoma: a single-arm, multicenter study. Targ Oncol. 2019;14(2):149–158.
   PubMed Web of Science ®Google Scholar
• Maruyama D, Nagai H, Maeda Y, et al. Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Sci. 2017;108(10):2061–2068.
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33(23):2492–2499.
   PubMed Web of Science ®Google Scholar
• Shi Y, Jia B, Xu W, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10(1):69.
   PubMedGoogle Scholar
• Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26(8):1766–1771.
   PubMed Web of Science ®Google Scholar
• Maruyama D, Tsukasaki K, Uchida T, et al. Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma. Ann Hematol. 2019;98(1):131–142.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Karlin L, Radford J, et al. European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma. Haematologica. 2016;101(10):e407–e410.
   PubMed Web of Science ®Google Scholar
• Ogura M, Ishida T, Hatake K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157–1163.
   PubMed Web of Science ®Google Scholar
• O’Connor O, Marchi E, Volinn W, et al. Strategy for assessing new drug value in orphan diseases: an international case match control analysis of the PROPEL study. JNCI Cancer Spectr. 2018;2(4):pky038.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7(1):11.
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827–5834.
   PubMed Web of Science ®Google Scholar
• Admojo L, Van Der Weyden C, Gao C, et al. A retrospective analysis of pralatrexate efficacy and tolerability in Australia. Presented at Blood 2018 Annual Scientific Meeting; 2018 Oct 21–24, 2018; Brisbane Convention & Exhibition Centre, Australia.
   Google Scholar
• Wang M-C, Ko B-S, Chiou T-J, et al. Interim update from a multi-center study of pralatrexate in Asian patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL). Presented at the 24th European Hematology Association Congress. 2019 Jun 15; Amsterdam, Netherlands.
   Google Scholar
• Kogure Y, Yoshimi A, Ueda K, et al. Modified ESHAP regimen for relapsed/refractory T cell lymphoma: a retrospective analysis. Ann Hematol. 2015;94(6):989–994.
   PubMed Web of Science ®Google Scholar